In this podcast, UROONCO RCC chief editor Dr. Maria Carmen Mir (ES) talks to Prof. Laurence Albiges (FR) on the abstract she recently presented at ASCO2024 - “Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomised phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection”.
Prof. Albiges details the two parts of the circulating biomarker analysis scheme, part one - biomarker identification/screening; and part two - assessing the association of circulating kidney injury molecule-1 with disease free survival outcomes.
The study results are discussed in detail and Prof. Albiges talks about what research is needed in the future to confirm the utility of circulating serum kidney injury molecule-1 in adjuvant RCC as a non-invasive biomarker.